CRISPR Therapeutics AG
CRSP
$48.41
-$2.04-4.04%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 2.44B | 1.98B | 1.92B | 1.72B | 1.86B |
| Total Receivables | -- | -- | -- | -- | -- |
| Inventory | -- | -- | -- | -- | -- |
| Prepaid Expenses | 6.18M | 5.95M | 9.88M | 8.93M | 8.83M |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | 400.00K | 3.89M | 3.50M | 3.50M | 3.50M |
| Total Current Assets | 2.45B | 1.99B | 1.93B | 1.73B | 1.87B |
|
|
|||||
| Total Current Assets | 2.45B | 1.99B | 1.93B | 1.73B | 1.87B |
| Net Property, Plant & Equipment | 240.85M | 247.58M | 255.49M | 262.57M | 269.70M |
| Long-term Investments | -- | -- | -- | -- | -- |
| Goodwill | -- | -- | -- | -- | -- |
| Total Other Intangibles | -- | -- | -- | -- | -- |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | 9.41M | 9.40M | 9.71M | 10.88M | 28.79M |
| Total Assets | 2.73B | 2.27B | 2.25B | 2.03B | 2.17B |
|
|
|||||
| Total Accounts Payable | 13.65M | 11.14M | 11.80M | 9.75M | 13.06M |
| Total Accrued Expenses | 28.96M | 34.46M | 24.90M | 27.37M | 28.29M |
| Short-term Debt | -- | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | 18.61M | 18.58M | 18.26M | 18.03M | 17.51M |
| Total Finance Division Other Current Liabilities | 75.06M | 84.95M | 64.00M | 49.21M | 60.59M |
| Total Other Current Liabilities | 75.06M | 84.95M | 64.00M | 49.21M | 60.59M |
| Total Current Liabilities | 136.29M | 149.12M | 118.96M | 104.36M | 119.45M |
|
|
|||||
| Total Current Liabilities | 136.29M | 149.12M | 118.96M | 104.36M | 119.45M |
| Long-Term Debt | 585.47M | -- | -- | -- | -- |
| Short-term Debt | -- | -- | -- | -- | -- |
| Capital Leases | 183.56M | 188.17M | 192.77M | 197.43M | 201.85M |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | 5.95M | 6.14M | 17.60M | 16.80M | 15.64M |
| Total Liabilities | 911.26M | 343.43M | 329.33M | 318.59M | 336.94M |
|
|
|||||
| Common Stock & APIC | 3.89B | 3.86B | 3.73B | 3.42B | 3.33B |
| Retained Earnings | -2.07B | -1.95B | -1.82B | -1.71B | -1.50B |
| Treasury Stock & Other | -2.00M | 4.76M | 4.93M | 3.98M | 4.07M |
| Total Common Equity | 1.81B | 1.92B | 1.92B | 1.71B | 1.83B |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | -- | -- | -- | -- | -- |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | -- | -- | -- | -- | -- |
|
|
|||||
| Total Common Equity | 1.81B | 1.92B | 1.92B | 1.71B | 1.83B |
| Total Preferred Equity | -- | -- | -- | -- | -- |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | 1.81B | 1.92B | 1.92B | 1.71B | 1.83B |
|
|
|||||